Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.54 |
| ▸ | FNTB | P49356 | 10/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12611461 | 0.94 | FNTA (0.56) | FNTAFNTBMEN1KMT2AMAPT | |
| SCHEMBL2002332 | 0.92 | CA9 (0.58) | FNTAFNTBMEN1KMT2AMAPT | |
| SCHEMBL1996715 | 0.91 | MEN1 (0.51) | FNTAFNTBMEN1KMT2AMAPT | |
| SCHEMBL1998094 | 0.89 | FNTA (0.55) | FNTAFNTBALDH1A1LMNA | |
| SCHEMBL2001883 | 0.83 | FNTA (0.61) | FNTAFNTBMEN1KMT2A | |
| SCHEMBL1995808 | 0.83 | TP53 (0.50) | FNTAFNTBMEN1KMT2AMAPT | |
| SCHEMBL2000109 | 0.83 | CA9 (0.52) | MEN1KMT2AMAPTALDH1A1CA12 | |
| SCHEMBL1996063 | 0.82 | CA9 (0.56) | FNTAFNTBMEN1KMT2AMAPT | |
| SCHEMBL1997044 | 0.81 | LMNA (0.56) | FNTAFNTBMEN1KMT2AMAPT | |
| SCHEMBL1998941 | 0.81 | FNTA (0.48) | FNTAFNTBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121427-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H LEE MOFFITT CANCER CT & RES (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210121427-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H LEE MOFFITT CANCER CT & RES (US) | 2021-04-29 | — | — | US | disclosed |
| US-10806712-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190192461-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H LEE MOFFITT CANCER CT & RES (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190192461-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H LEE MOFFITT CANCER CT & RES (US) | 2019-06-27 | — | — | US | disclosed |
| US-10226439-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170202795-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H LEE MOFFITT CANCER CT & RES (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170202795-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H LEE MOFFITT CANCER CT & RES (US) | 2017-07-20 | — | — | US | disclosed |
| US-9604923-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | H.LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604923-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | H.LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20140329900-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329900-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110201576-A1 | Small molecule inhibitors of stat3 with anti-tumor activity | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201576-A1 | Small molecule inhibitors of stat3 with anti-tumor activity | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2011-08-18 | — | — | US | disclosed |
| US-7960434-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960434-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090069420-A1 | Small molecule inhibitors of STAT3 with anti-tumor activity | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069420-A1 | Small molecule inhibitors of STAT3 with anti-tumor activity | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2007136858-A2 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202795-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | STAT3, STAT1, STAT5A | FNTA 2310/4885FNTB 1660/4885MEN1 2273/4885 |
| US-20210121427-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | STAT3, STAT1, STAT5A | FNTA 2310/4885FNTB 1660/4885MEN1 2273/4885 |
| US-20110201576-A1 | Small molecule inhibitors of stat3 with anti-tumor activity | STAT3, STAT1, STAT5A | FNTA 2310/4885FNTB 1660/4885MEN1 2273/4885 |
| US-20090069420-A1 | Small molecule inhibitors of STAT3 with anti-tumor activity | STAT3, STAT1, STAT5A | FNTA 2310/4885FNTB 1660/4885MEN1 2273/4885 |
| US-20140329900-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | STAT3, STAT1, JAK2 | FNTA 1951/4885FNTB 1421/4885MEN1 2507/4885 |
| US-20190192461-A1 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY | STAT3, STAT1, STAT5A | FNTA 2310/4885FNTB 1660/4885MEN1 2273/4885 |
| US-10226439-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | STAT3, STAT1, STAT5A | FNTA 2310/4885FNTB 1660/4885MEN1 2273/4885 |
| US-10806712-B2 | Small molecule inhibitors of STAT3 with anti-tumor activity | STAT3, STAT1, STAT5A | FNTA 2310/4885FNTB 1660/4885MEN1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.